Three months after revealing that its respiratory syncytial virus (RSV) preventive antibody clesrovimab had passed muster in a phase 2b/3 trial, Merck is putting numbers to the claim. Clesrovimab ...

AIM Vaccine Co., Ltd. has secured clinical trial approval for its mRNA-based RSV vaccine, developed by its subsidiary Liverna Therapeutics Inc. This marks a significant step forward for the ...

What is this silent virus that endangers Filipino Seniors with comorbidities? Respiratory Syncytial Virus (RSV) is not just another cold or flu—it is potentially life- threatening for seniors ...

Beyfortus is the first long-acting antibody approved in Canada for the prevention of RSV lower respiratory tract disease in newborns and infants through their first RSV season. Sanofi noted that ...

In years prior to the availability of an RSV vaccine, an estimated 60,000 to 160,000 RSV-associated hospitalizations and 6,000 to 10,000 RSV-associated deaths occurred annually among U.S. adults ...

The Centers for Disease Control and Prevention (CDC) recently warned that respiratory syncytial virus (RSV) and mycoplasma pneumonia, or “walking pneumonia,” are on the rise among very young ...

This comprehensive guide about Microsoft Azure includes common use cases, technical limitations, and what to know before adopting the cloud computing platform. https://assets.techrepublic.com ...

On Tuesday, the FDA approved Pfizer Inc’s (NYSE:PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, to prevent lower respiratory tract ...

Oct. 18, 2024 – Older people who aren’t sure about whether to get the vaccine for respiratory syncytial virus (RSV) now have a new set of data to help them make up their minds. A large study ...

Poll Finds Public Fears Over RSV Have Eased, Although It Remains a Threat By Dennis Thompson HealthDay Reporter WEDNESDAY, Oct. 16, 2024 (HealthDay News) -- Public concerns about contracting RSV ...

(Reuters) -GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third ...